Overview

Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia

Status:
Terminated

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to determine whether SPD489 40 mg, 100 mg, and 160 mg are effective and safe in the treatment of Negative Symptoms of Schizophrenia (NSS).

Phase:

Phase 3

Details

Lead Sponsor:

Shire

Treatments:

Antipsychotic Agents
Lisdexamfetamine Dimesylate